619 related articles for article (PubMed ID: 29733872)
61. Monitoring disease response to tyrosine kinase inhibitor therapy in CML.
Hughes TP; Branford S
Hematology Am Soc Hematol Educ Program; 2009; ():477-87. PubMed ID: 20008233
[TBL] [Abstract][Full Text] [Related]
62. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
63. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
64. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
65. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
[TBL] [Abstract][Full Text] [Related]
66. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
Rittavee Y; Artus J; Desterke C; Simanic I; de Souza LEB; Riccaldi S; Coignard S; Ijjeh Y; Hugues P; Bennaceur-Griscelli A; Turhan AG; Foudi A
Exp Hematol; 2023 Feb; 118():40-52. PubMed ID: 36535407
[TBL] [Abstract][Full Text] [Related]
67. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
68. Imatinib restores expression of CD62L in BCR-ABL-positive cells.
Fruehauf S; Topaly J; Schad M; Paschka P; Gschaidmeier H; Zeller WJ; Hochhaus A; Ho AD
J Leukoc Biol; 2003 May; 73(5):600-3. PubMed ID: 12714574
[TBL] [Abstract][Full Text] [Related]
69. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
70. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
71. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
Moschovi M; Adamaki M; Athanasiadou A; Divane A; Karytianou A; Tourkantoni N
Leuk Lymphoma; 2015; 56(8):2460-2. PubMed ID: 25641431
[No Abstract] [Full Text] [Related]
72. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
Ye Y; Yang X; Li F; Liu W; Zhang W; Huang Z
Animal Model Exp Med; 2024 Apr; 7(2):136-144. PubMed ID: 36300552
[TBL] [Abstract][Full Text] [Related]
73. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
74. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene.
Mu HJ; Xie R; Shen YF; Jiang YQ; Zeng YJ
Br J Biomed Sci; 2009; 66(1):20-4. PubMed ID: 19348122
[TBL] [Abstract][Full Text] [Related]
75. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
[TBL] [Abstract][Full Text] [Related]
76. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
Cea M; Cagnetta A; Cirmena G; Garuti A; Rocco I; Palermo C; Pierri I; Reverberi D; Nencioni A; Ballestrero A; Gobbi M; Carella AM; Patrone F
Leuk Lymphoma; 2013 Feb; 54(2):342-52. PubMed ID: 22762548
[TBL] [Abstract][Full Text] [Related]
77. Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas Cdo C; Ferreira da Cunha A; Brugnerotto AF; Gambero S; de Almeida MH; Carazzolle MF; Pagnano KB; Traina F; Costa FF; de Souza CA
Leuk Lymphoma; 2014 Aug; 55(8):1861-9. PubMed ID: 24144310
[TBL] [Abstract][Full Text] [Related]
78. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
[TBL] [Abstract][Full Text] [Related]
79. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Liu Y; Shao Z; Liao Y; Xia X; Huang C; He J; Hu T; Yu C; Jiang L; Liu J; Huang H
Eur J Pharmacol; 2020 Sep; 883():173366. PubMed ID: 32679184
[TBL] [Abstract][Full Text] [Related]
80. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
